Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Mammary Neoplasms, Animal × exemestane × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 225 Neoplasm Metastasis 19 Neoplasms 9 Breast Neoplasms, Male 7 Breast Diseases 6 Ovarian Neoplasms 4 Carcinoma, Intraductal, Noninfiltrating 4 Recurrence 3 Obesity 3 Endometrial Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Breast Carcinoma In Situ 3 Breast Cancer Metastatic 3 Advanced Breast Cancer 3 Prostatic Neoplasms 2 Neoplasms by Site 2 Multiple Endocrine Neoplasia Type 1 2 Carcinoma, Renal Cell 2 Bulbo-Spinal Atrophy, X-Linked 2 Arthralgia 2 Vitamin D Deficiency 1 Uterine Cervical Neoplasms 1 Unilateral Breast Neoplasms 1 Tuberous Sclerosis 1 Triple Negative Breast Neoplasms 1 Thoracic Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sleep Wake Disorders 1 Skin Diseases 1 Sexuality 1

Interventions

exemestane 1 entinostat 1 Mammography 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00676663 2022-05-11

ENCORE301

Syndax Pharmaceuticals

Phase 2 Completed

130 enrolled 18 charts

Breast Neoplasms, Mammary Neoplasms, Animal

Data powered by HemOnc (CC BY 4.0) Colophon ⚡